Eliquis (apixaban) is a blood thinner that has been linked with uncontrollable bleeding injuries, sometimes due to medical malpractice by improper prescriptions. Known also as Apixaban, manufactured in a joint venture by Pfizer and Bristol-Myers Squib, it is prescribed to help reduce the risk of stroke due to atrial fibrillation. Eliquis was marketed as a superior blood thinner because it does not require regular blood monitoring.
We have already filed suits and are continuing to investigate claims on behalf of injured users suffering from gastrintestinal bleeding or inra-cranial hemmoraghe leading to hospitalization. Our firm handles a case from start to finish. If you or someone you know has suffered from a bleeding injury due to taking this drug the New York product liability lawyers at Rheingold Giuffra Ruffo & Plotkin LLP are here to help you explore your legal options.
Learn more about the adverse effects of Eliquis and how your injury could entitle you to legal action by calling (212) 684-1880.
With other drugs, such as warfarin, bleeding was easy to stem by using vitamin K. However, Eliquis belongs to a group of new anticoagulants that do not have reversal agents to stop their blood-thinning effects in case of a bleeding event. This can lead to life-threatening consequences. Other injuries from Eliquis include rectal bleeding, intestinal bleeding and brain hemorrhaging. Other drugs included in this new group of anticoagulants called direct thrombin inhibitors are Pradaxa, Xarelto, Zontivity and Savaysa.
Eliquis is not recommended in patients with severe hepatic impairment. In regards to patients with moderate hepatic impairment, there is also no clear understanding of the impact of hepatic impairment on the coagulation cascade and its relationship to effectiveness and bleeding. Since patients with moderate hepatic impairment may have inherent clotting abnormalities and there is limited clinical familiarity in these patients, dosing recommendations cannot be provided. In Xarelto, a similar drug to Eliquis, multiple studies have reported users having abnormal liver function tests.
Although it has not yet been consolidated due to its novelty, we expect the Eliquis litigation to eventually be consolidated into a Multi District Litigation (MDL). This is standard practice in the field of drug products liability. In fact, Xarelto, a very similar drug to Eliquis, was recently consolidated into an MDL in the U.S. District Court for the Easter District of Louisiana. Our lawyers have handled thousands of MDL cases and are happy to help future clients resolve their cases.
Our firm has extensive experience in evaluating medical malpractice claims, especially in conjunction with prescription drugs and medical devices. When we confidentially review potential claims, we investigate the following issues:
News has surfaced over the last year of errors and frauds made in the clinical study of Eliquis before it was marketed, including the altering of side effect data. To this date the sellers have never revealed to the medical profession what these concealments were. A physician in the Food and Drug Administration criticized the study due to these errors. Details of the clinical trial errors can be found on Bloomberg News (Chinese Trial Misconduct Delayed Bristol-Myers Medicine), Forbes (Roller Coaster Path to Approval for Eliquis Uncovered by FDA Documents), and Hemaotlogy Times (Fraud, error were behind delay of apixaban approval), amongst other sources.